Veterinary Pain Management Market Size (2024 - 2029)

Veterinary Pain Management Market Analysis

The Veterinary Pain Management Market size is estimated at USD 1.65 billion in 2024, and is expected to reach USD 2.20 billion by 2029, growing at a CAGR of 5.91% during the forecast period (2024-2029).

The global outbreak of COVID-19 impacted the veterinary pain management market, adversely affecting the supply chain of veterinary products. For instance, in April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and the supply chain of livestock products during the pandemic, which slowed down the supply of veterinary products. However, the high adoption rate of pet animals during the lockdown increased the demand for veterinary pain management drugs. For instance, according to the PDSA PAW report published in June 2021, 2.0 million people in the United Kingdom adopted pets between March 2020 to May 2021. Therefore, owing to such factors, the market has started to gain momentum and is expected to maintain an upward trend over the forecast period.

The growth in the prevalence of painful and inflammatory diseases in animals, the rise in the need for easily accessible and affordable treatment options, and the increase in awareness about animal health and welfare are the major drivers of the market. For instance, according to an article published by Morris Animal Foundation in March 2021, osteoarthritis affects around 14.0 million adult dogs in the United States every year, and owners have consistently reported it as a top health concern among pets. Similarly, according to an article published by American Animal Health Association in April 2021, approximately 6.0 million dogs are diagnosed with cancer each year. The same source also stated that around one in four dogs would develop cancer at some point, and nearly 50.0% of dogs older than ten would develop some form of cancer.

Per the report published by the CDC in September 2021, Bovine Spongiform Encephalopathy (BSE) is one of the most prevalent chronic diseases among cattle in Canada. The report stated that the true prevalence of Bovine Spongiform Encephalopathy (BSE) in Canada was around 90.0%, which is higher than the prevalence of BSE in the United States (3.0 to 8.0 cases per million in Canada and around 0.167 cases per million in the United States). Such a high prevalence of diseases is anticipated to propel the demand for veterinary pain management drugs, thereby boosting the market's growth.

Rising initiatives by the government and other organizations are also expected to positively impact the market. For instance, in October 2020, FECAVA launched a campaign titled "FECAVA Basic Practices in Anesthesia and Analgesia," which includes important lectures around Europe in the upcoming years and a series of six ready-to-use, printable posters/infographics regarding anesthesia and pain management in animals. Such supportive initiatives are expected to create new opportunities for the market in the coming years.

New product launches by the key players in the market are also expected to propel the market's growth. For instance, in January 2022, the US FDA approved Zorbium (buprenorphine transdermal solution), the first transdermal buprenorphine animal medication for post-surgical pain management in cats. This approval provides veterinarians with another option for controlling postoperative pain in cats. Thus, owing to such factors, considerable market growth is anticipated over the forecast period.

However, side effects associated with treatment and the high cost of certain products are likely to impede the market growth over the forecast period.

Veterinary Pain Management Industry Segmentation

Veterinary pain management refers to a medical approach toward the prevention, diagnosis, and treatment of pain caused by several factors, such as physical trauma, internal organ problems, surgical procedures, brain and spine problems, slipped discs, arthritis, and joint damage. 

The veterinary pain management market is segmented by product (drugs and devices), application (osteoarthritis and joint pain, postoperative pain, cancer, and other applications), animal type (companion and livestock), end user (hospitals and clinics, retail outlets, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries. The report offers the value (in USD million) for the above segments.